Drug Trial Radar · NCT02933281
MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa
Last checked: Nov 19, 2026Latest source record: Feb 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
144
Actual
Start
May 14, 2018
Primary completion
Sep 5, 2021
Study completion Sep 5, 2021
Sponsor
- Lead sponsor
- International AIDS Vaccine InitiativeResearch network
- Sponsor type
- Research network
- Collaborators
- Biofabri, S.L; Universidad de Zaragoza; South African Tuberculosis Vaccine Initiative
- First posted
- Oct 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
MTBVAC at four dose levels: 5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU. The active control is BCG (5 x 10\^5 CFU). Participants will receive a single dose of MTBVAC or BCG revaccination administered intradermally on Study Day 0.
Conditions
- Tuberculosis
Interventions
MTBVACBiological
Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU
BCGBiological
BCG 5 x 10\^5 CFU
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and reactogenicity of MTBVAC at escalating dose levels compared to BCG vaccine by assessing number of participants with AEs and SAEsTime frame: Study Days 0 to Day 365
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SATVI: Worcester
Worcester, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.